Top Markets
Coin of the day
Histogen Inc. Histogen Inc.

Histogen Inc.

HSTO
株式のランク #40869
Histogen Inc. operates as a clinical-stage biotechnology company, focusing on... Histogen Inc. operates as a clinical-stage biotechnology company, focusing on the development of novel, stem cell-free biologic products derived from its proprietary hypoxia-generated growth factor technology platform. Among its offerings is HST-003, a human extracellular matrix, currently undergoing Phase 1/2 clinical trials to mend articular cartilage defects in the knee. Additionally, the company is advancing HST-004, a cell-conditioned media solution designed for spinal disc repair, and Emricasan, an orally active pan-caspase inhibitor targeting COVID-19 treatment. In its preclinical pipeline, Histogen is developing CTS-2090 and CTS-2096. These are selective caspase-1 inhibitors formulated to suppress inflammasome activation and intervene in a range of inflammation-mediated conditions. Founded in 2007, Histogen Inc. maintains its headquarters in San Diego, California.
株価
$0.02765
最終同期: 2024-12-23
時価総額
$69.04K
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Histogen Inc. (HSTO)

カテゴリー

Histogen Inc.(HSTO)のP/B比率
August 2026 時点のP/B比率 TTM: 0.00
Histogen Inc. の最新の財務報告および株価によると、現在のP/B比率(TTM)は 0.00 です。2021 年末時点でのP/B比率は 0.06 でした。
Histogen Inc. の P/B 比率の履歴(2011 ~ 2026)
各年末時点のP/B比率
P/B比率 変化
2026 (TTM) 0.00 -77.50%
2022 0.02 -69.01%
2021 0.06 -31.54%
2020 0.09 -168.39%
2019 -0.13 -166.48%
2018 0.19 -59.34%
2017 0.47 -13.89%
2016 0.55 -98.24%
2015 31.05 -52.41%
2014 65.25 265.13%
2013 17.87 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
同業他社のP/B比率
企業 P/B比率 P/B比率の差
6.2613 139,040.00%
US
6.3483 140,973.33%
NL
- -
CH
- -
KR
3.634 80,655.56%
BE